

## Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- [Viracta](#) Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the H.C. Wainwright BIOCONNECT Virtual Conference.

The pre-recorded webcast will be available for on-demand viewing beginning Monday, January 10, 2022, at 7:00 a.m. ET on the Investors section of the Viracta website under "Events and Webcasts" at <https://viracta.investorroom.com/events-and-webcasts>. The webcast will be archived for 90 days.

### **About Viracta Therapeutics, Inc.**

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a pivotal Phase 2 clinical trial for EBV-positive (EBV<sup>+</sup>) lymphoma and a Phase 1b/2 trial in patients with EBV<sup>+</sup> nasopharyngeal carcinoma and other EBV<sup>+</sup> solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit [www.viracta.com](http://www.viracta.com).

### **Investor Relations Contact:**

Ashleigh Barreto  
Head of Investor Relations & Corporate Communication  
Viracta Therapeutics, Inc.  
[abarreto@viracta.com](mailto:abarreto@viracta.com)

SOURCE Viracta Therapeutics, Inc.

---

<https://viracta.investorroom.com/2022-01-04-Viracta-Therapeutics-to-Present-at-the-H-C-Wainwright-BIOCONNECT-Virtual-Conference>